REGISTER RECORD · clinicaltrials.gov
NCT05625087
Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib
AS THE REGISTER RECORDS IT
Status and dates
| Status as listed | ACTIVE_NOT_RECRUITING: running, but no longer enrolling |
|---|---|
| Register last updated | 2025-08-20 |
| Retrieved by this site | 2026-08-31 |
| Source | https://clinicaltrials.gov/study/NCT05625087 |
What this record shows
This entry describes research activity. It is not a statement about market authorisation, and it is not regulatory, legal or medical advice: a trial being listed, completed or halted says nothing about whether a substance may be sold or used anywhere. Status wording is reproduced as the register writes it and is never mapped onto a simpler vocabulary.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.